Veterinary Vaccines Market to Reach USD 17.33 Billion by 2036 at 5.2% CAGR; Brazil Leads at 6.5%, Germany Trails at 5.0%

NEWARK, Del., September 30, 2026 - According to Future Market Insights (FMI), the global veterinary vaccines market is projected to increase from USD 10.44 billion in 2026 to USD 17.33 billion by 2036, expanding at a 5.2% CAGR during the forecast period. The market was valued at USD 9.92 billion in 2025 and is expected to create an incremental opportunity of USD 6.89 billion between 2026 and 2036.

Demand is being supported by government-led animal disease control programs, increasing vaccination coverage in livestock production, companion animal preventive care, and stronger disease surveillance. Large-scale programs for foot-and-mouth disease, brucellosis, avian diseases, and other notifiable conditions are sustaining vaccine procurement across major agricultural markets.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-409

Key Market Highlights

· Market Size (2026): USD 10.44 billion

· Forecast Value (2036): USD 17.33 billion

· CAGR (2026-2036): 5.2%

· Incremental Opportunity: USD 6.89 billion

· Leading Product: Live Attenuated Vaccines, with 38.0% share in 2026

· Leading Animal Segment: Livestock Animals, with 57.0% share

· Leading Disease Indication: Foot and Mouth Disease, with 26.0% share

· Leading Route of Administration: Injection, with 61.0% share

· Fastest-Growing Country: China, at 7.9% CAGR

· Second-Fastest-Growing Country: India, at 7.5% CAGR

Global Segment Leaders

Live Attenuated Vaccines - 38.0% Share: Live attenuated vaccines are projected to remain the leading product category in 2026. FMI attributes demand to their strong and durable immune responses and established use in large-scale livestock disease prevention programs.

Livestock Animals - 57.0% Share: Livestock represents the largest animal segment, supported by commercial cattle and poultry production, routine vaccination programs, food-security requirements, and the need to limit economic losses from infectious disease outbreaks.

Foot and Mouth Disease - 26.0% Share: Foot and mouth disease represents the leading disease-indication segment. Government vaccination campaigns and disease-surveillance programs continue to support demand, particularly in regions with large livestock populations.

Injection - 61.0% Share: Injectable administration leads the route-of-administration segment because it provides consistent dosing and established clinical efficacy across routine livestock and companion animal vaccination programs.

Veterinary Hospitals and Clinics: Veterinary clinics remain an important distribution channel, particularly for professional administration, preventive care, disease diagnosis, and companion animal vaccination.

Country-Level Performance

· China - 7.9% CAGR (2026-2036): Mandatory vaccination programs, swine herd rebuilding, and domestic production expansion.

· India - 7.5% CAGR (2026-2036): National FMD and brucellosis vaccination programs and expanding poultry vaccination.

· Brazil - 6.5% CAGR (2026-2036): Livestock vaccination procurement and poultry export-certification requirements.

· United States - 6.1% CAGR (2026-2036): Companion animal vaccination and regulatory oversight of veterinary biologics.

· United Kingdom - 5.7% CAGR (2026-2036): Companion animal vaccination and structured livestock disease programs.

· Germany - 5.0% CAGR (2026-2036): High companion animal vaccination rates and established veterinary vaccine manufacturing.

FMI identifies China as the fastest-growing market among the countries shown in its country comparison table, at 7.9% CAGR through 2036. Mandatory vaccination programs covering foot-and-mouth disease, highly pathogenic avian influenza, and other notifiable diseases contribute to government-funded procurement. Post-African swine fever herd rebuilding is also supporting investment in swine vaccination and biosecurity programs.

India follows at 7.5% CAGR. FMI links demand to the National Animal Disease Control Programme, including large-scale vaccination against foot-and-mouth disease and brucellosis, alongside broader poultry vaccination and increasing urban companion animal vaccination.

Brazil is listed at 6.5% in FMI's country comparison table, with the country's individual section highlighting mandatory FMD vaccination across its cattle herd, poultry vaccination requirements linked to export certification, and expanding companion animal vaccination demand.

The United States is listed at 6.1% in the report's country comparison table. FMI's detailed country section separately states 6.8%, citing established companion animal vaccination protocols and USDA-APHIS oversight of veterinary biologics. Germany is listed at 5.0% in the comparison table, while its detailed section states 6.2%, citing strong companion animal vaccination rates and the presence of major veterinary vaccine manufacturers.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-409

Market Drivers, Restraints and Opportunities

Government vaccination programs remain an important demand driver. Mandatory and structured immunization initiatives for livestock diseases create recurring procurement requirements while disease surveillance increases the emphasis on preventive animal health.

The livestock segment also benefits from commercial farming expansion and the need to protect cattle and poultry productivity. Routine vaccination is increasingly integrated into production systems to reduce disease-related losses and support food-supply security. Companion animal vaccination provides another source of recurring demand through veterinary clinic visits and preventive-care programs.

The market continues to face challenges related to regulatory certification, manufacturing requirements, infrastructure gaps in some emerging markets, and the time required to qualify new products. FMI also identifies capital-intensive manufacturing infrastructure and established customer relationships as barriers to market entry.

Opportunities are emerging through recombinant and other advanced vaccine technologies, expanded companion animal vaccination, regional manufacturing, and new disease-management applications. Suppliers with localized production and distribution capabilities can address procurement priorities around availability and supply continuity.

Competitive Landscape

The veterinary vaccines market includes global animal-health companies competing through manufacturing scale, product breadth, technical capabilities, regulatory expertise, and geographic distribution.

Zoetis Services LLC., Merck & Co., Inc. (MSD Animal Health), Bioveta, Inc., and Elanco (Eli Lilly) are identified by FMI among the major global competitors. Ceva, Boehringer Ingelheim International GmbH, and Kemin Industries, Inc. have established regional positions, while Hester Biosciences, Phibro Animal Health Corporation, and Virbac participate through differentiated technologies and specialized or regional applications.

FMI identifies production scale, technical capability, geographic coverage, regulatory compliance, supply reliability, and cost competitiveness as important factors shaping competition. Buyers are increasingly consolidating procurement among suppliers capable of meeting documentation, traceability, and performance requirements across multiple markets.

Recent Industry Developments

· Zoetis invested $590 million in 2025 in a new Georgia facility to expand its U.S. manufacturing footprint for animal-health biologics and vaccine products.

· Merck & Co. (MSD Animal Health) received a positive European regulatory opinion in 2025 for INNOVAX®-ND-IBD-ILT, a single-dose poultry vaccine designed to provide combined protection against four major poultry diseases.

· Boehringer Ingelheim launched a new poultry vaccine range in 2025, including VAXXITEK® HVT+IBD+H5 in Egypt for high-risk poultry markets.

Analyst Perspective

Anurag Sharma, Principal Consultant at Future Market Insights, states:

"Companies that can improve cost competitiveness while delivering consistent performance across core industrial applications are likely to strengthen their position over the forecast period. The veterinary vaccines market is moving toward a consolidated competitive structure where production scale, compliance readiness, and application depth determine market positioning. Procurement behavior is shifting toward longer-cycle supply agreements that reward operational reliability and documented traceability. Growth through 2036 is expected to concentrate among suppliers that combine production efficiency with regulatory documentation capability, particularly in markets where compliance thresholds are rising."

Report Scope

The Veterinary Vaccines Market is segmented by:

· Product: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines, DNA Vaccines

· Animal: Livestock Animals, Companion Animals, Aquaculture Animals

· Disease Indication: Foot and Mouth Disease, Rabies, Newcastle Disease, Brucellosis

· Route of Administration: Injectable, Oral, Intranasal

· Distribution Channel: Veterinary Hospitals and Clinics, Pharmacies, Online Sales, Distributors

· Regions: North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa

· Forecast Period: 2026-2036

The study covers 30+ countries, including China, India, Brazil, the United States, the United Kingdom, Germany, and Japan.

Access Full Report: https://www.futuremarketinsights.com/reports/veterinary-vaccines-market

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and animal health.

Related Reports:

· https://plaza.rakuten.co.jp/nk99fmi/diary/202608120002/

· https://plaza.rakuten.co.jp/nk99fmi/diary/202608120003/

· https://plaza.rakuten.co.jp/nk99fmi/diary/202608120004/

· https://plaza.rakuten.co.jp/nk99fmi/diary/202608120005/

· https://plaza.rakuten.co.jp/nk99fmi/diary/202608120006/

Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For Web - https://www.futuremarketinsights.com

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, medical devices, and pharmaceuticals.

This release was published on openPR.